Genomics

Dataset Information

0

IKAROS facilitates antigen escape in the face of CD19- and CD22-targeted therapies for B-cell malignancies

ABSTRACT: This SuperSeries is composed of the SubSeries listed below.

ORGANISM(S): Homo sapiens

PROVIDER: GSE225755 | GEO | 2025/03/26

REPOSITORIES: GEO

Json Xml

Dataset's files

Source:
Action DRS
Other
Items per page:
1 - 1 of 1

Similar Datasets

Unknown IKAROS levels are associated with antigen escape in CD19- and CD22-targeted therapies for B-cell malignancies.
| S-EPMC12019336 | biostudies-literature
Genomics IKAROS facilitates antigen escape in the face of CD19- and CD22-targeted therapies for B-cell malignancies
| PRJNA937281 | ENA
Unknown CD34+CD19-CD22+ B-cell progenitors may underlie phenotypic escape in patients treated with CD19-directed therapies.
| S-EPMC9346957 | biostudies-literature
Unknown Subsequent Malignancies After CD19-Targeted Chimeric Antigen Receptor T Cells in Patients With Lymphoma.
| S-EPMC11427145 | biostudies-literature
Unknown A retrospective comparison of CD19 single and CD19/CD22 bispecific targeted chimeric antigen receptor T cell therapy in patients with relapsed/refractory acute lymphoblastic leukemia.
| S-EPMC7572410 | biostudies-literature
Unknown Novel cellular therapies for leukemia: CAR-modified T cells targeted to the CD19 antigen.
| S-EPMC5536093 | biostudies-literature
Unknown Preclinical Development of Bivalent Chimeric Antigen Receptors Targeting Both CD19 and CD22.
| S-EPMC6300726 | biostudies-literature
Unknown CD19/CD22 bispecific chimeric antigen receptor‑NK‑92 cells are developed and evaluated.
| S-EPMC10161343 | biostudies-literature
Unknown Dual specific CD19/CD22-targeted chimeric antigen receptor T-cell therapy for refractory diffuse large B-cell lymphoma: A case report.
| S-EPMC7405542 | biostudies-literature
Unknown How I prevent infections in patients receiving CD19-targeted chimeric antigen receptor T cells for B-cell malignancies.
| S-EPMC7441168 | biostudies-literature